The University of Chicago is one of the leading academic institutions in the United States. More Nobel laureates have been affiliated with this University than any other institution in the world. The section of urology shares in this heritage as a result of the work of Dr. Charles Huggins, who was awarded the Nobel Prize in Medicine in 1966 for his discovery of hormone therapy for the treatment of advanced prostate cancer. The section of urology continues this commitment to excellence in clinical practice and basic research. The goals of our residency program are to provide excellent comprehensive clinical training in all aspects of urology and to create an atmosphere for discovery by providing active research. Thus, we endeavor to provide our residents with the best training in clinical urology while enabling them to advance the science of urology through investigation.
In the past five years, there has been great transition and growth in the section of urology. Under the leadership of Dr. Arieh Shalhav, the section recruited four additional full-time faculty members and one molecular biologist. Over that time, surgical volume has tripled and the number of complex adult and pediatric urology cases has increased dramatically. Additionally, we now have 12 laboratory investigators, including full-time faculty members, medical students, graduate students and post-graduate fellows.
Our urology clinic is located in the Duchossois Center for Advanced Medicine (DCAM) at the University of Chicago Medicine campus. This clinic was designed to allow further growth and to serve the needs of the section, which includes 5,000 square feet of space with two complete sets of four examination rooms each, a cystoscopy suite and separate high-end facilities with urodynamics and transrectal ultrasonography. In February 2005, the 155-bed Comer Children's Hospital opened. This hospital is directly across the street from the adult hospital and includes dedicated pediatric operating rooms as well as state-of-the-art neonatal and pediatric intensive care units.
In 2002, the section recruited Dr. Arieh Shalhav from Indiana University to establish a program in minimally invasive urologic surgery. In past 11 years, Dr. Shalhav has developed one of the leading minimally invasive urology programs in the Midwest. He has built a busy clinical and successful academic program. He and his colleagues have now performed more than 5,000 major minimally invasive surgical procedures, including more than 3,000 robotic-assisted laparoscopic radical prostatectomies. He has established both clinical and research fellowships. He also has an active animal research laboratory in which all residents receive training in minimally invasive surgery and in which there are several interesting ongoing research projects including a study on the effects of different energy devices on cavernosal nerve injury.
In 2006, Dr. Shalhav became the interim chief and in April, 2007, Dr. Shalhav assumed the leadership of the section of urology as the Fritz and Mary Lee Duda Family Professor.
In 2007, Dr. Glenn Gerber, a senior member of our faculty, was appointed the urology residency program director devoting a significant amount of his time managing the residency program. In 2010, Dr. Gerber led the resident complement increase from two to three residents per year.
In 2007, Dr. Mohan Gundeti joined our faculty as assistant professor after completing his fellowship training in pediatric urology at the Great Ormond Street Hospital for Sick Children in London, England in 2006. Dr. Gundeti rapidly developed a practice in minimally invasive reconstructive pediatric urology. Our two PGY-4 (UR-3) residents each spend six months in pediatric urology.
In 2008, Dr. Scott Eggener joined the faculty as assistant professor after completing a three-year urologic oncology fellowship at Memorial Sloan Kettering. Dr. Eggener's primary focus is patients with testes and kidney cancer.
In 2008, NorthShore University Health Systems and the University of Chicago's Pritzker School of Medicine had agreed on an academic affiliation. Since that time the NorthShore urology group, led by Dr. Michael McGuire, joined our team as affiliated faculty. We now place medical students, residents and fellows from the University of Chicago Medicine at the three hospital locations in Evanston, Glenbrook and Highland Park for a portion of their educational experience.
In 2009, Dr. Donald VanderGriend joined the faculty as assistant professor and director of urologic stem cell research. Dr. VanderGriend received his Ph.D. in cancer biology from the University of Chicago. From there he conducted a post-doctoral fellowship at the Brady Urological Institute and the department of oncology at Johns Hopkins University in the laboratory of Dr. John Isaacs. His post-doctoral work focused on prostate stem cells as they relate to normal prostate function and androgen signaling. He continues his work on stem cells as they relate to carcinogenesis and differentiation.
In 2010, Dr. Norm Smith joined the faculty as associate professor of urology and now concurrently served as co-director of urologic oncology. He was selected for the prestigious American Urological Association Leadership Program class of 2010-2011. His specialty interest is urologic oncology, and more specifically, bladder and prostate cancer.
In 2010, Dr. Doreen Chung, who completed her fellowship in voiding dysfunction, incontinence and female urology at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, joined our faculty.
In 2010, Dr. Gary Steinberg was the recipient of an Endowed Chair from the Bruce and Beth White Family Professorship in Urologic Oncology. Dr. Steinberg is the head of our oncology program and today our bladder cancer program is one of the five most prominent in the country.
In 2011, Dr. David Rebuck joined our faculty and is based primarily at Mount Sinai Hospital.
In 2013, the University of Chicago opened their new hospital pavilion, The Center for Care and Discovery, on campus in Hyde Park. Our new hospital is a 10-story "hospital for the future" that will serve as the new core of the campus of the University of Chicago Medicine. An architectural and technological tour de force, this new hospital provides a home for complex specialty care with a focus on cancer, gastrointestinal disease, neuroscience, advanced surgeryand high-technology medical imaging. This new hospital contains 240 single-occupancy inpatient rooms including 60 intensive care beds; 28 operating rooms with leading-edge technology; two floors of expansion space for future technology; and an integrated diagnostic and interventional platform including cardiac, gastrointestinal, neurological and vascular services.